A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
NCT07619339
This study is recruiting at 7 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The researchers are doing this study to find out whether the combination of tepotinib and ivonescimab is a safe and effective treatment for people with non-small cell lung cancer (NSCLC) that is positive for METex14 skipping. The researchers will test up to two different doses of tepotinib in combination with ivonescimab to find the best dose of tepotinib that causes few or mild side effects in participants.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Last updated on ClinicalTrials.gov
- September 16, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 3
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) · Basking Ridge, NJ
- Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, NJ
- Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, NJ
New York · 4
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ) · Commack, NY
- Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, NY
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) · New York, NY
- Memorial Sloan Kettering Nassau (All Protocol Activities) · Uniondale, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.